Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis

American Journal of Clinical Dermatology

Volumn 3, Issue 6, 2002, Pages 381-388

  Reitamo, Sakari ^a   Remitz, Anita ^a   Kyllönen, Hannele ^a   Saarikko, Johanna ^a   Granlund, Håkan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CELL RECEPTOR; CORTICOSTEROID; FK 506 BINDING PROTEIN; IMMUNOMODULATING AGENT; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BASOPHIL; BINDING AFFINITY; BIOAVAILABILITY; CARCINOGENESIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG SAFETY; HELPER CELL; HUMAN; INFLAMMATORY CELL; LANGERHANS CELL; MAST CELL; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ATROPHY; T LYMPHOCYTE ACTIVATION; WOUND HEALING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; HUMANS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0036348475     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203060-00002     Document Type: Review

References (66)

1. Diagnostic features of atopic dermatitis
2. Atopic dermatitis: From the genes to skin lesions
3. Atopic dermatitis
4. Antipruritic effect of oral cyclosporin A in atopic dermatitis
5. A multicentre, double-blind, placebo-controlled crossover study to assess the efficacy and safety of cyclosporin in adult patients with severe refractory atopic dermatitis
6. Cyclosporin A in atopic dermatitis: Time to relapse and effect of intermittent therapy
7. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis
8. Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis
9. Topical cyclosporine and contact dermatitis in guinea pig and man
10. Inhibition of contact allergy reaction by topical FK 506
11. Tacrolimus ointment for atopic dermatitis
12. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment
13. A short-term trial of tacrolimus ointment for atopic dermatitis
14. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children
15. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
16. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
17. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
18. Atopic dermatitis: New insights and opportunities for therapeutic intervention
19. The 500 Dalton rule for the skin penetration of chemical compounds and drugs
20. Treatment of lichenified atopic eczema with tacrolimus ointment
21. Eczematous reactions in atopic dermatitis caused by epicutaneous testing with inhalant allergens
22. Basophils in allergen-induced patch test sites in atopic dermatitis
23. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema
24. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506)
25. Induction of corticosteroid insensitivity in human peripheral blood mononuclear cells by microbial superantigens
26. Tacrolimus (FK506): New treatment approach in superantigen-associated diseases like atopic dermatitis?
27. Roles of Th1 and Th2 in a murine model of allergic dermatitis
28. The mechanism of action of cyclosporin A and FK506
29. Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction
30. Tacrolimus: A new topical immunomodulatory therapy for atopic dermatitis
31. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
32. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen presenting dendritic cells in atopic dermatitis
33. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes
34. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
35. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists
36. SDZ ASM 981 inhibits anti-IgE stimulated mediator release in human dermal mast cells
37. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions
38. FK 506, a novel immunosuppressant isolated from a streptomyces, I: Fermentation, isolation, and physio-chemical and biological characteristics
39. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis
40. Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis
41. Evidence for a disease promoting effect of S. aureus-derived exotoxins in atopic dermatitis
42. Nuclear factor of activated T cells transcription factor NFATp controls superantigen-induced lethal shock
43. Effect of hydrocortisone, methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo
44. Changes in collagen I and collagen III metabolism in patients with generalized atopic eczema undergoing medium-dose ultraviolet Al phototherapy
45. Inhibition of type 1 collagen production by dermal fibroblasts upon contact with activated T cells
46. Potent costimulation of effector T lymphocytes by human collagen type I
47. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts
48. Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines
49. Collagens serve as an extracellular store of bioactive interleukin 2
50. Allergen-specific immune deviation from a Th2 to a Th1 response induced by dendritic cells and collagen type I
51. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
52. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: A randomised, double-blind controlled study
53. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
54. SDZ ASM 981 cream 1% effective in the treatment of pediatric atopic dermatitis: Two 6-week, randomized, double-blind, vehicle-controlled, multi-center studies with 20-week open-label phases
55. Long-term management with SDZ ASM 981 cream 1% in atopic dermatitis patients
56. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety
57. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents
58. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis
59. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis
60. Safe and effective long-term treatment of atopic dermatitis with SDZ ASM 981 1% cream
61. Are we going OTT about ITT?
62. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
63. Increasing incidence of eczema herpeticum: Analysis of seventy-five cases
64. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis
65. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome
66. Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis